Professional
Added to YB: 2025-09-05
Pitch date: 2025-09-03
ACHV [bullish]
Achieve Life Sciences, Inc.
+66.31%
current return
Author Info
DF Research shares (mostly) short-biased research from Dalrymple Finance. Sign up for the newsletter.
Company Info
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
Market Cap
$149.2M
Pitch Price
$2.79
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.09
P/E
-2.00
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
ACHV: The Countdown Begins
ACHV: Submitted NDA for Cytisinicline (1st new smoking cessation drug in 20yrs) to FDA in June; approval decision expected late Q2'26. Targeting 29M US smokers + growing alt-nicotine users. Two-pronged strategy: Big Pharma partnership or launch with Omnicom. Est $8-16/share buyout value (2.5-5x return). $260-500M revenue potential vs generic Chantix. Recent $45M raise provides runway through buyout timeline.
Read full article (5 min)